Consensus cost-effectiveness model for treatment of chronic hepatitis B in Asia Pacific countries

Hepatology International

Volumn 8, Issue 3, 2014, Pages 382-394

  Dan, Yock Young ^a   Wong, John B ^b   Hamid, Saeed S ^c   Han, Kwang Hyub ^d   Jia, Ji Dong ^e   Liu, Chun Jen ^f   Piratvisuth, Teerha ^g   Lok, Anna S F ^h   Lim, Seng Gee ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c AGA KHAN UNIVERSITY HOSPITAL   (Pakistan)

^d Yonsei University College of Medicine   (South Korea)

^e CAPITAL MEDICAL UNIVERSITY   (China)

^f NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^g PRINCE OF SONGKLA UNIVERSITY   (Thailand)

^h UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Antiviral treatment; Cirrhosis; Cost effectiveness; Hepatitis B; Hepatocellular carcinoma; Markov modeling

Indexed keywords

ADEFOVIR; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; LAMIVUDINE PLUS TENOFOVIR DISOPROXIL; NUCLEOSIDE ANALOG; PEGINTERFERON; TELBIVUDINE; TENOFOVIR; VIRUS DNA;

ANTIVIRAL RESISTANCE; ARTICLE; ASIA; ATTITUDE TO HEALTH; CHINA; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; CONSENSUS DEVELOPMENT; CONSULTATION; COST EFFECTIVENESS ANALYSIS; DECOMPENSATED LIVER CIRRHOSIS; DEVELOPING COUNTRY; DRUG COST; DRUG EFFICACY; EVIDENCE BASED PRACTICE; HEALTH CARE COST; HEALTH CARE POLICY; HEPATITIS B; HOSPITALIZATION; HUMAN; INCIDENCE; KOREA; LABORATORY TEST; LIFE EXPECTANCY; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MONOTHERAPY; MORTALITY; PAKISTAN; PATIENT COUNSELING; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SINGAPORE; SOCIOECONOMICS; TAIWAN; THAILAND; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS INHIBITION; VIRUS LOAD;

EID: 84905570338     PISSN: 19360533     EISSN: 19360541     Source Type: Journal    
DOI: 10.1007/s12072-014-9549-1     Document Type: Article

References (27)

1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepatitis. 2004;11(2):97-107 (Pubitemid 38365759)
2. Lesmana LALN-Y, Mahachai V, Phiet PH, Suh DJ, Yao GB, Hepatitis B. Overview of the burden of disease in the Asia-Pacific region. Liver Int. 2006;26(s2):3-10 (Pubitemid 44697930)
3. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology (Baltimore, Md.) 2009;50(3):661-662. Epub 2009/08/29
4. European Association For The Study Of The L. EASL. Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol. 2009;50(2):227-242 Epub 2008/12/05
5. Liaw Y-F, Kao JH, Piratvisuth T, Chan HLY, Chien R-N, Liu C-J, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hep Int. 2012;6(3):531-561 Epub 17 May 2012
6. Sung JJ, Amarapurkar D, Chan HL, Cheng J, Kao JH, Han KH, et al. Treatment of chronic hepatitis B in Asia-Pacific countries: is the Asia-Pacific consensus statement being followed? Antivir Ther. 2010;15(4):607-616 Epub 2010/07/01
7. Kanwal F, Gralnek IM, Martin P, Dulai GS, Farid M, Spiegel BM. Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis. Ann Int Med. 2005;142(10):821-831 (Pubitemid 40664041)
8. Dakin H, Bentley A, Dusheiko G. Cost-utility analysis of tenofovir disoproxil fumarate in the treatment of chronic hepatitis B. Value Health. 2010;13(8):922-933 Epub 2010/09/10
9. Veenstra DL, Sullivan SD, Clarke L, Iloeje UH, Tafesse E, Di Bisceglie A, et al. Cost effectiveness of entecavir versus Lamivudine with Adefovir salvage in HBeAg-positive chronic hepatitis B. PharmacoEconomics. 2007;25(11):963-977 (Pubitemid 350014529)
10. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide.Med DecisMaking. 1993;13(4):322-338 (Pubitemid 24013155)
11. Keeffe EB, Zeuzem S, Koff RS, Dieterich DT, Esteban-Mur R, Gane EJ, et al. Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol. 2007;5(8):890-897 Epub 2007/07/17
12. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006;130(3):678-686 (Pubitemid 43374518)
13. Chen CF, Lee WC, Yang HI, Chang HC, Jen CL, Iloeje UH, et al. Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma. Gastroenterology 2011;141(4):1240-1248, 8 e1-2. Epub 2011/06/28
14. Lee HW, Lee HJ, Hwang JS, Sohn JH, Jang JY, Han KJ, et al. Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B. Hepatology (Baltimore, Md.). 2010;51(2):415-421 Epub 2009/11/11
15. Gane EJ, Marcellin P, Sievert W, Trinh HN, Shiffman ML, Washington MK, et al. Five years of treatment with Tenofovir Df (Tdf) for chronic hepatitis B (Chb) infection in Asian patients is associated with sustained viral suppression and significant regression of histological fibrosis and cirrhosis. Hepatology (Baltimore, Md.). 2011;54:1038a-1039a
16. National Wages and Productivity Commission P. Asian Wages. 2010 [cited 2012 05082012]; Available from: http://nwpc.dole.gov.ph/pages/statistics/ Asean%20Wages%202010.pdf
17. Ong SC, Mak B, Aung MO, Li SC, Lim SG. Health-related quality of life in chronic hepatitis B patients. Hepatology (Baltimore, Md.). 2008;47(4):1108 Epub 2008/03/05
18. Shamliyan TA, MacDonald R, Shaukat A, Taylor BC, Yuan JM, Johnson JR, et al. Antiviral therapy for adults with chronic hepatitis B: a systematic review for a National Institutes of Health Consensus Development Conference. Ann Int Med. 2009;150(2):111-124 Epub 2009/01/07
19. WHO. Macroeconomics and health: investing in health for economic development.Report of theCommission onMacroeconomics and Health: Executive Summary. World Health Organisation. 2001
20. Hong WW, Ang LW, Cutter JL, James L, Chew SK, Goh KT. Changing seroprevalence of hepatitis B virus markers of adults in Singapore. Ann Acad Med Singapore. 2010;39(8):591-598 Epub 2010/09/15
21. Statistics Do. Yearbook of Statitistics Singapore 1999
22. Registry SC. Cancer Registry Interim Report For The Period 2003-2007. 2009
23. Statistics Do. Yearbook of Statitistics Singapore 2009. 2009
24. Agency CI. The World Factbook. Country Comparison:Life Expectancy at Brith. 2011
25. Reijnders JG, Perquin MJ, Zhang N, Hansen BE, Janssen HL. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B. Gastroenterology. 2010;139(2):491-498 Epub 2010/04/13
26. Belongia EA, Costa J, Gareen IF, Grem JL, Inadomi JM, Kern ER, et al. NIH consensus development statement on management of hepatitis B. NIH Consens State Sci Statements. 2008;25(2):1-29 Epub 2008/10/25
27. Dai CY, Tseng TC, Wong GL, Huang JF, Wong VW, Liu CJ, et al. Consolidation therapy for HBeAg-positive Asian chronic hepatitis B patients receiving lamivudine treatment: a multicentre study. J Antimicrob Chemother. 2013;68(10):2332-2338 Epub 2013/06/27